Brief: Hua Medicine Announces Positive Results Of Combination Study Of Dorzagliatin With Empagliflozin (A Sglt-2 Inhibitor)
27/04/2020 01:40
April 27 (Reuters) - Hua Medicine 2552.HK :
* ANNOUNCES POSITIVE RESULTS OF COMBINATION STUDY OF
DORZAGLIATIN
WITH EMPAGLIFLOZIN (A SGLT-2 INHIBITOR)
* CLINICAL STUDY IS PHASE I TRIAL CONDUCTED IN U.S. IN TYPE
2
DIABETES (T2D) PATIENTS WITH INSUFFICIENTLY CONTROLLED BLOOD
GLUCOSE LEVELS
Source text for Eikon: urn:newsml:reuters.com:*:nHKS4y4d0P
Further company coverage: 2552.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hua Medicine
See all newsBrief: Hua Medicine Expects Loss Of RMB30.2 Mln For HY
Brief: Hua Medicine Posts Profit For The Year RMB1.11 Billion
Brief: Hua Medicine Says Dorzagliatin Approved For Marketing In Hong Kong SAR
Brief: Hua Medicine Posts H1 Revenue Of RMB 217.4 Million
Brief: Hua Medicine Expects RMB1,184.1 Million Profit For HY